Berlin, Germany, September 18, 2019, 08.00 a.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today its participation and poster presentation at the European Society for Medical Oncology (ESMO) Congress on September 27 - October 1, 2019 at Fira Gran Via, Av. Joan Carles, 64, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.

**Poster Title:** Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer

The poster will be presented on Sunday, September 29 from 12.00-01.00 p.m. CEST in Hall 4 and the authors will be available for questions. The poster will also be uploaded to the NOXXON website.

The abstract which is based on an earlier interim dataset will be published on Monday, September 23, at 00.05 a.m. CEST on the ESMO website.

Aram Mangasarian, CEO of NOXXON, and Dr. Jarl Ulf Jungnelius, CMO, will host a webcast poster presentation on September 30, 2019, at 09.00 a.m. CEST, to discuss the data from this trial and its relevance for further clinical development of NOX-A12. The presentation will be followed by a Q&A session. To join the webcast, please send an email to webcast@noxxon.com.

For more information, please contact:

**NOXXON Pharma N.V.**
Aram Mangasarian, Ph.D., Chief Executive Officer
Tel. +49 (0) 30 726247 0
amangasarian@noxxon.com

**Trophic Communications**
Gretchen Schweitzer or Joanne Tudorica
Tel. +49 (0) 89 2388 7730 or +49 (0) 176 2103 7191
schweitzer@trophic.eu

**NewCap**
Alexia Faure
Tel. +33 (0) 1 44 71 98 51
afaure@newcap.fr
**About NOXXON**

NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor microenvironment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 has delivered top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in December 2018 and further studies are being planned in these indications. In September 2019 the company initiated an additional trial with NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination. Further information can be found at: [www.noxxon.com](http://www.noxxon.com)

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp

[https://www.linkedin.com/company/noxon-pharma-ag](https://www.linkedin.com/company/noxon-pharma-ag)

[https://twitter.com/noxon_pharma](https://twitter.com/noxon_pharma)

**Disclaimer**

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.